From: The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis
Total (N = 293) | Tertile 1 (N = 99) | Tertile 2 (N = 97) | Tertile 3 (N = 97) | P | |
---|---|---|---|---|---|
FIB, g/L | 1.50 (1.02–2.18) | 0.86 (0.70–1.03) | 1.51 (1.38–1.72) | 2.59 (2.18–3.33) | < 0.001 |
Male, n (%) | 183 (62.5) | 62 (62.6) | 60 (61.9) | 61 (62.9) | 0.988 |
Age, years | 53 (41–64) | 51 (33–64) | 56 (39–62) | 55 (46–66) | 0.118 |
ANC, \(\times \hspace{0.17em}\)109/L | 1.32 (0.69–2.35) | 1.04 (0.57–2.11) | 1.36 (0.77–2.24) | 1.55 (0.81–2.71) | 0.057 |
HB, g/L | 86 (71–100) | 84 (77–95) | 90 (73–107) | 82 (68–97) | 0.111 |
PLT,\(\times \hspace{0.17em}\)109/L | 43 (24–72) | 31 (18–52) | 45 (25–80) | 54 (32–97) | < 0.001 |
ALT, U/L | 67.1 (36.3–149.1) | 98.6 (50.6–235.4) | 77.6 (32.4–143.2) | 50.1 (28.4–82.3) | < 0.001 |
AST, U/L | 91 (46.1–203.8) | 178.5 (78.1–411.0) | 90.2 (45.1–198.1) | 61.0 (39.5–121.65) | < 0.001 |
LDH, U/L | 676 (394.0–1308.5) | 1004 (580.0–1793.0) | 646 (354.5–1101.0) | 540 (379.5–934.0) | < 0.001 |
TG, mmol/L | 2.47 (1.71–3.70) | 2.78 (1.77–4.04) | 2.52 (1.89–3.67) | 2.01 (1.58–3.18) | 0.015 |
Ferritin, ug/L | 4739 (1522–12,798) | 8133 (2000–20,000) | 3639 (1613–9558) | 2841 (1494–7095) | < 0.001 |
sCD25, ng/L | 33,480 (17,442–51,668) | 40,042 (22,660–55,919) | 26,920 (14,266–48,289) | 32,939 (16,018–47,762) | 0.024 |
β2-MG, mg/L | 5.97 (4.41–8.53) | 5.91 (4.19–8.53) | 7.63 (4.85–9.28) | 5.69 (3.88–8.04) | 0.030 |
Fever, °C | 39.5 (39.0–40.0) | 39.6 (39.0–40.0) | 39.4 (39.0–40.0) | 39.3 (39.0–40.0) | 0.143 |
Splenomegaly (%) | 260 (88.7) | 90 (90.9) | 88 (90.7) | 82 (84.5) | 0.278 |
Lymphadenopathy (%) | 152 (51.9) | 45 (45.5) | 52 (53.6) | 55 (56.7) | 0.265 |
Hemophagocytic (%) | 260 (88.7) | 88 (88.9) | 85 (87.6) | 87 (89.7) | 0.900 |
HScore, points | 234 (205–269) | 255 (224–283) | 235 (210–274) | 219 (179–244) | < 0.001 |
EBV infection (%) | 148 (50.5) | 65 (65.7) | 44 (45.4) | 39 (40.2) | 0.001 |
Etiology | 0.120 | ||||
MHLH (%) | 169 (57.7) | 65 (65.7) | 50 (51.5) | 54 (55.7) | |
Non-MHLH (%) | 124 (42.3) | 34 (34.3) | 47 (48.5) | 43 (44.3) | |
Treatment | 0.960 | ||||
Chem ± HLH-94 (%) | 167 (57.0) | 58 (58.6) | 53 (54.6) | 56 (57.7) | |
GC ± IVIG ± CsA ± VP16 (%) | 112 (38.2) | 36 (36.4) | 40 (41.2) | 36 (37.1) | |
Support (%) | 14 (4.8) | 5 (5.1) | 4 (4.1) | 5 (5.2) |